Tametraline

Tametraline is a serotonin reuptake inhibitor that was under development by the pharmaceutical company Pfizer in the 1970s. It is related in chemical structure to the antidepressants sertraline (Zoloft) and tramadol, but it was never marketed.

History

Tametraline was originally developed by Pfizer in the 1970s to address the need for new antidepressant therapies. Despite showing promise in early trials, the development of tametraline was discontinued for unknown reasons. It is speculated that this may have been due to the development of other, more effective antidepressants around the same time.

Pharmacology

Tametraline acts as a serotonin reuptake inhibitor, increasing the amount of serotonin available in the brain. This is similar to the action of many other antidepressants. However, tametraline also has some structural similarities to the opioid analgesic tramadol, which may suggest additional mechanisms of action.

Related Compounds

Tametraline is chemically related to the antidepressant sertraline (Zoloft), which is also a serotonin reuptake inhibitor. Both drugs were developed by Pfizer. Tametraline is also structurally similar to the opioid analgesic tramadol.

See Also

• Serotonin reuptake inhibitor
• Pfizer
• Sertraline
• Tramadol

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia